Sunday, November 30 | 2:30 p.m.-2:40 p.m. | S5-SSOB01-1 | Room S501
Attendees will learn about how contrast-enhanced ultrasound (CEUS) can significantly improve the detection of ovarian malignancies.
Shabnam Grover, MD, from Sharda University in Greater Noida, India, in her talk will discuss how CEUS improves the performance of conventional risk assessment models and can evaluate ovarian-adnexal masses.
Ovarian malignancies have high mortality rates due to asymptomatic early-stage and late-stage diagnosis. While O-RADS is used to assess risk in the U.S., European guidelines follow the International Ovarian Tumor Analysis (IOTA) algorithms.
The team’s study included 89 patients with 100 adnexal masses, with ultrasound tumor evaluation performed by O-RADS and IOTA strategies. While one IOTA strategy, the Assessment of Different NEoplasias in adneXa-ADNEX-Model (IOTA-ADNEX), performed best in standalone accuracy with 88%. With CEUS integration, though, O-RADS had the best performance. This included 100% sensitivity, 95% specificity, 97% positive predictive value, 100% negative predictive value, and 98% diagnostic accuracy.
The research will also highlight CEUS’s advantages, such as being more accessible and economical than contrast-enhanced MRI (CE-MRI). This may especially help in underserved areas, they added.
“Further, since CEUS contrast-agents are excreted through respiration, this technique can be safely applied in patients with deranged renal functions, wherein gadolinium-CE-MRI is contraindicated,” the team wrote in its abstract.
Learn more by attending this session.